Jade Biosciences, Inc. (JBIO)
NASDAQ · Healthcare
$19.67-5.70%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $683.51M
- P/E ratio
- —
- EPS
- —
- Volume
- 626,410
- 52-week high
- —
- 52-week low
- —
- Open
- $20.82
- Day high
- $21.50
- Day low
- $19.25
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$127.41M | -$3.19 |
| 2024 | — | -$46.98M | -$14.89 |
| 2023 | — | -$75.52M | -$2.87 |
| 2022 | — | -$51.51M | -$2.10 |
| 2021 | — | -$22.96M | -$1.87 |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
- CEO
- Tom Frohlich
- Employees
- 50
- Country
- US
- IPO date
- Apr 29, 2025
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Jade Biosciences, Inc.'s stock price today?
- JBIO is trading at $19.67 as of Jul 20, 2026.
- What is Jade Biosciences, Inc.'s market cap?
- Jade Biosciences, Inc. (JBIO) has a market capitalization of $683.51M.
- Does Jade Biosciences, Inc. pay a dividend?
- Jade Biosciences, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Jade Biosciences, Inc. in?
- Jade Biosciences, Inc. operates in the Healthcare sector.